Meeting
2018 ASCO Annual Meeting
Iconic: Peri-operative immuno-chemotherapy in operable oesophageal and gastric cancer.
Authors
Sonia Mansukhani
The Institute of Cancer Research, London, United Kingdom
Sonia Mansukhani , Michael Davidson , Angela Gillbanks , Clare Peckitt , Annette Musallam , Ruwaida Begum , Daniel Morganstein , Andrew Wotherspoon , Angela M. Riddell , James M Kinross , Julian Marchesi , Katharina von Loga , William H. Allum , Sheela Rao , David J. Watkins , Ian Chau , David Cunningham , Naureen Starling , Asif Chaudry , Marco Gerlinger
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT03399071
Citation
J Clin Oncol 36, 2018 (suppl; abstr TPS4139)
DOI
10.1200/JCO.2018.36.15_suppl.TPS4139
Abstract #
TPS4139
Poster Bd #
324a
Abstract Disclosures
Similar Posters
Poster
2021 ASCO Annual Meeting
MONEO: A phase II study of avelumab (Av) plus FLOT in the peri-operative treatment for patients (pts) with resectable gastric or gastroesophageal junction cancer (GC).
First Author: MARIA ALSINA
First Author: Salah-Eddin Al-Batran
Poster
2022 ASCO Gastrointestinal Cancers Symposium
A randomized phase 3 study evaluating the efficacy and safety of first-line pembrolizumab plus lenvatinib plus chemotherapy versus chemotherapy in patients with advanced/metastatic gastroesophageal adenocarcinoma: LEAP-015.
First Author: Deirdre Jill Cohen
Poster
2021 ASCO Annual Meeting
Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma.
First Author: Hongli Li